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Abstract
Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-based screening may
be more efficient. We investigated whether CRC screening based on polygenic risk is a cost-effective alternative to current
uniform screening, and if not, under what conditions it would be.
Methods: The MISCAN-Colon model was used to simulate a hypothetical cohort of US 40-year-olds. Uniform
screening was modeled as colonoscopy screening at ages 50, 60, and 70 years. For risk-stratified screening, individuals
underwent polygenic testing with current and potential future discriminatory performance (area under the receiver-
operating curve [AUC] of 0.60 and 0.65–0.80, respectively). Polygenic testing results were used to create risk groups, for
which colonoscopy screening was optimized by varying the start age (40–60 years), end age (70–85 years), and interval
(1–20 years).
Results: With current discriminatory performance, optimal screening ranged from once-only colonoscopy at age 60 years for
the lowest-risk group to six colonoscopies at ages 40–80 years for the highest-risk group. While maintaining the same health
benefits, risk-stratified screening increased costs by $59 per person. Risk-stratified screening could become cost-effective if
the AUC value would increase beyond 0.65, the price per polygenic test would drop to less than $141, or risk-stratified screen-
ing would lead to a 5% increase in screening participation.
Conclusions: Currently, CRC screening based on polygenic risk is unlikely to be cost-effective compared with uniform screen-
ing. This is expected to change with a greater than 0.05 increase in AUC value, a greater than 30% reduction in polygenic test-
ing costs, or a greater than 5% increase in adherence with screening.
Colorectal cancer (CRC) is the second most common cause of
cancer death in the United States, with more than 51 000 deaths
expected in 2019 (1). Fortunately, screening and early treatment
of adenomas and CRC can prevent CRC death (2). Randomized,
controlled trials have shown that CRC mortality can be reduced
by 15–30% with fecal occult blood testing, and by 40% with flexi-
ble sigmoidoscopy screening (3–5). Colonoscopy screening is
expected to achieve an even higher mortality reduction (6).
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Of US adults who were up to date with screening in 2012,
two-thirds were screened by colonoscopy (7). Because this is an
invasive procedure, with the potential for serious complications
(8), it could be argued that those who would not have been diag-
nosed with CRC in the absence of screening (approximately 95%
of the population) face unnecessary risks of colonoscopy
screening. Meanwhile, others may have had a better prognosis
if screening would have detected their disease at an earlier
time. If screening could be more targeted, then mortality could
be reduced in those at increased CRC risk, while harms could be
reduced in those at decreased CRC risk. To identify those at in-
creased or decreased risk, exploratory studies have suggested
the use of polygenic risk profiling (9, 10).
Polygenic risk prediction differs from commonly described
hereditary CRC syndromes by its focus on multiple single nucle-
otide polymorphisms (SNPs) instead of a single genetic muta-
tion. For individuals with identified inherited syndromes that
are caused by a single genetic mutation, such as Lynch syn-
drome, more intensive screening is already recommended (11).
The 2–5% of CRC cases that can be attributed to high-penetrance
genes causing these types of syndromes account for only a
small fraction of the total heritability of CRC, which has been es-
timated at 12–35% (12,13). A comprehensive whole-genome se-
quencing study and meta-analysis of genome-wide association
studies recently identified 40 new independent signals for CRC,
bringing the number of known independent signals for CRC to
about 100 (14). Together, these signals explain approximately
11% of the familial relative risk in US individuals (14). As more
genetic variants associated with CRC risk are detected, this per-
centage could potentially increase to 73% (15). Another study
suggested that if all variants were identified, at least 7.42% of all
CRC cases would be explained by SNPs (16).
The benefits of screening based on polygenic risk will de-
pend on the discriminatory accuracy of risk-stratification algo-
rithms in identifying those who will develop CRC, as expressed
by the area under the receiver-operating characteristic curve
(AUC). With the currently identified common genetic variants,
the AUC value of polygenic testing is approximately 0.6 (17,18).
As more variants are discovered, this value may further in-
crease. In this study, we estimated whether risk-stratified
screening would be a cost-effective alternative to current uni-
form screening, and if not, under what conditions it would be.
Methods
We used the Microsimulation Screening Analysis-Colon
(MISCAN-Colon) model to simulate a population at average
risk for CRC that is willing to undergo polygenic testing and
subsequent risk-stratified colonoscopy screening. We com-
pared the results of such risk-stratified screening with those
of current uniform screening, with colonoscopies at ages 50,
60, and 70 years (19).
MISCAN-Colon
MISCAN-Colon is a well-established microsimulation model for
CRC developed at the Department of Public Health of the
Erasmus University Medical Center (Rotterdam, the
Netherlands) (20). The structure, underlying assumptions, and
calibration of the model are described in previous publications
and in the Model Appendix (available online) (20,21). In brief,
MISCAN-Colon simulates the life histories of a large population
from birth until death. As each simulated person ages, one or
more adenomas may develop. These adenomas can progress
from small (5 mm), to medium (6–9 mm), to large size
(10 mm). Some adenomas can develop into preclinical cancer,
which may progress through stages I to IV. During each stage
CRC may be diagnosed because of symptoms. Survival after
clinical diagnosis is determined according to the stage at diag-
nosis, the localization of the cancer, and the person’s age (22).
Screening will alter some simulated life histories through
cancer prevented by adenoma detection and removal, or can-
cers detected at earlier stages resulting in more favorable sur-
vival estimates. However, screening can also result in serious
complications, as well as overdiagnosis and overtreatment of
CRC (ie, the detection and treatment of cancers that would not
have been detected without screening). By comparing a simula-
tion of life histories with screening to a simulation of the same
life histories without screening, MISCAN-Colon quantifies the
effectiveness of screening, as well as the associated harms and
costs.
Simulated Population in MISCAN-Colon
We simulated a cohort of 40-year-olds with US life expectancy
and followed them until death (23). At model initiation, each in-
dividual is assigned an underlying baseline risk of developing
adenomas. An adenoma can be either progressive (ie, may
cause cancer dependent on the duration) or nonprogressive (ie,
will never cause cancer). Once a progressive adenoma has de-
veloped, the duration until cancer development is randomly
drawn, and it does not depend on any individual-based risk
level.
Polygenic Testing
By testing for the presence of risk alleles that are associated
with CRC, a polygenic test can estimate someone’s relative risk
(RR) of developing CRC. The larger the number of risk alleles in-
cluded in such a test, the more accurate its estimate of some-
one’s risk, and the higher its AUC value. A previously published
method was used to generate the RR distribution in hypotheti-
cal populations with varying AUC values of polygenic testing of
0.60, 0.65, 0.70, 0.75, and 0.80 (Supplementary Appendix Figure 1
available online) (24,25). We split the simulated population into
groups of estimated RR for cancer, using an elliptical copula in
R. This method assigned an individual to an RR group as a func-
tion of underlying baseline risk and discriminative accuracy of
the polygenic test: The higher the AUC value, the higher the cor-
relation of estimated RR and underlying baseline risk (see
Technical Appendix available online for details). For risk-
stratified screening, each population was split into RR groups,
with RR varying from less than 0.1 to 0.1 to 5.9 with increments
of 0.1 to greater than 5.9, yielding 60 groups.
Screening and Surveillance
We simulated scenarios without screening and with colonos-
copy screening at intervals of 1, 2, 3, 5, 7, 10, 15, and 20 years. In
addition, different begin ages (40, 45, 50, 55, and 60 years) and
different end ages (70, 75, 80, and 85 years) for screening were
considered. Test characteristics of colonoscopy are shown in
Figure 1.
Individuals with adenomas detected and removed at screen-
ing were assumed to undergo colonoscopy surveillance accord-
ing to current guidelines (35). Because surveillance is meant to














Small adenomas (≤5 mm) 75%b
Medium-sized adenomas (6–9 mm) 85%b
Large adenomas (≥10 mm) 95%b
Colorectal cancer 95%b
Reach 95% reaches the cecum; the reach of the remaining 5% is 
distributed uniformly over colon and rectum
Complicaon rate for posive test
Serious gastrointesnal eventc Age-specificd
Other gastrointesnal evente Age-specificf
Cardiovascular eventg Age-specifich
Mortality rate




Per complicaon of colonoscopy
Serious gastrointesnal eventc 0.0055
Other gastrointesnal evente 0.0027
Cardiovascular eventg 0.0048




Stage I CRC 0.12 0.05 0.70 0.05
Stage II CRC 0.18 0.05 0.70 0.05
Stage III CRC 0.24 0.24 0.70 0.24
Stage IV CRC 0.70 0.70 0.70 0.70
Costs (2014 US$)m,n




Per complicaon of colonoscopy
Serious gastrointesnal eventc 11 142
Other gastrointesnal evente 7587
Cardiovascular eventg 8453




Stage I CRC 36 883 3106 64110 19 331
Stage II CRC 49 475 2918 63 856 17 429
Stage III CRC 60 033 4068 67353 21 620
Stage IV CRC 78 124 12 274 88 749 50 122
Figure 1. Model inputs: test characteristics, utility loss, and costs of colorectal cancer screening and treatment. a) We assumed that in 14% of all negative colonoscopies
a nonadenomatous lesion was detected, resulting in a polypectomy or a biopsy, respectively. b) The sensitivity of colonoscopy for the detection of adenomas and CRC
within the reach of the endoscope was obtained from a systematic review on miss rates observed in tandem colonoscopy studies (26). c) Serious gastrointestinal events
are perforations, gastrointestinal bleeding, or transfusions. d) Formula: 1/[exp(9.27953  0.06105  Age) þ 1]  1/[exp(10.78719  0.06105  Age) þ 1]. e) Other gastroin-
testinal events are paralytic ileus, nausea and vomiting, dehydration, or abdominal pain. f) Formula: 1/[exp(8.81404  0.05903  Age) þ 1]  1/[exp(9.61197  0.05903 
Age) þ 1]. g) Cardiovascular events are myocardial infarction or angina, arrhythmias, congestive heart failure, cardiac or respiratory arrest, syncope, hypotension, or
shock. h) Formula: 1/[exp(9.09053  0.07056  Age) þ 1]  1/[exp(9.38297  0.07056  Age) þ 1]. i) Risk of dying from a colonoscopy at age 65 (Warren et al. [27], Gatto
et al. [28], and van Hees et al. [29]) j) The loss of quality of life associated with a particular event. k) Care for CRC was divided in three clinically relevant phases: initial,
continuing, and terminal care. The initial care phase was defined as the first 12 months after diagnosis; the terminal care phase was defined as the final 12 months of
life; the continuing care phase was defined as all months in between. In the terminal care phase, we distinguished between CRC patients dying from CRC and CRC
patients dying from another cause. For patients surviving less than 24 months, the final 12 months were allocated to the terminal care phase, and the remaining
months were allocated to the initial care phase. l) Utility losses for LYs with initial care were derived from a study by Ness and colleagues (30). For LYs with continuing
care for stage I and II CRC, we assumed a utility loss of 0.05 QALYs; for LYs with continuing care for stage III and IV CRC, we assumed the corresponding utility losses
for LYs with initial care. For LYs with terminal care for CRC, we assumed the utility loss for LYs with initial care for stage IV CRC. For LYs with terminal care for another
cause, we assumed the corresponding utility losses for LYs with continuing care. m) Costs include copayments and patient time costs (ie, the opportunity costs of
spending time on screening or being treated for a complication or CRC), but do not include travel costs, costs of lost productivity, and unrelated health-care and non–
health-care costs in added years of life. We assumed that the value of patient time was equal to the median wage rate in 2014: $17.09 per hour (31). We assumed that
colonoscopies used up 36 hours; serious gastrointestinal complications 192 hours; other gastrointestinal complications 96 hours; and cardiovascular complications
120 hours of patient time. Patient-time costs associated with CRC care were provided by Yabroff (personal communication) and were calculated using the methodology
described in a study by Yabroff and colleagues (32). n) In sensitivity analyses, all costs except those of polygenic testing were increased to reflect commercial rates
rather than Medicare reimbursement; see Supplementary Appendix Table 1 (available online) (33). o) Polygenic testing costs for CRC risk were based on the price of a
currently available polygenic test (34). Alternative values ($100 and $300) were considered in sensitivity analyses. QALY ¼ quality-adjusted life-year; LY ¼ life-year; CRC
¼ colorectal cancer.
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follow individuals at increased risk more closely, the recom-
mended surveillance interval was shortened for strategies for
which it would have been longer than the screening interval.
We assumed that surveillance continued until 5 years after the
end age of screening.
Adherence
In the base-case analysis, we assumed full adherence to poly-
genic testing, colonoscopy screening, and colonoscopy surveil-
lance because we aim to estimate screening outcomes for those
willing to undergo screening. In sensitivity analyses, we as-
sumed percentages that are more realistic, based on observed
adherence rates in the United States (36).
Costs and Utilities
The assumed loss in quality of life attributed to CRC screening
was 0.002 quality-adjusted life-years (QALYs) per colonoscopy
(1.5 days at 0.5 utility) and 0.0027–0.0055 QALYs per complica-
tion of colonoscopy (2–4 days at 0.5 utility) (Figure 1). We also as-
sumed that life-years (LYs) with CRC are of lower quality than
those without CRC (30).
The cost-effectiveness analyses were conducted from a
modified societal perspective. We included both direct medical
costs, as well as time costs both for the patient and a patient es-
cort. However, direct non–health-care costs such as travel
expenses were not included (37). The costs of colonoscopies
were based on 2014 Medicare payment rates and copayments
(Figure 1). For complications, the average payment by Centers
for Medicare and Medicaid Services (CMS) was calculated by
type of complication using frequency data on hospitalizations
for colonoscopy complications from Craig Parzynski, MS, of Yale
University (personal communication). Net costs of CRC care
were obtained from an analysis of Surveillance, Epidemiology,
and End Results–Medicare–linked data (38) (personal communi-
cation, Robin Yabroff, PhD, and Martin Brown, PhD, both for-
merly of the National Cancer Institute). Patient-time costs and
copayments were added to all these estimates, which were then
updated to 2014 US dollars using the Consumer Price Index (39).
For polygenic testing, we assumed a cost of $200 based on the
price of currently available polygenic tests (34).
Analyses and Outcomes
For every level of underlying baseline risk, we simulated all
screening strategies to quantify their QALYs and costs as com-
pared with no screening. For uniform screening, we simply cal-
culated a weighted sum of the results of colonoscopy screening
at ages 50, 60, and 70 years over all underlying risk groups. For
risk-stratified screening, we first calculated QALYs and costs by
estimated RR group for every screening strategy as a weighted
average of the outcomes by underlying risk within that estimated
RR group. Next, we used these results to determine the optimal
screening strategy by estimated RR group. Finally, the costs and
effects of all optimal strategies were summed to obtain overall
outcomes for risk-stratified screening (see Technical Appendix
available online for details).
For risk-stratified screening, the willingness-to-pay (WTP)
threshold was set to the level at which the QALYs gained were
equal to those of uniform screening. This enabled a fair compar-
ison of the costs of uniform vs risk-stratified screening. In the
results we show the costs of both strategies, as well as the cost
savings when uniform screening would be replaced with risk-
stratified screening. We applied the conventional 3% annual
discount rate both for costs and effects.
Sensitivity Analyses
In one-way sensitivity analyses, we varied:
the costs of polygenic testing – assuming a price per test
of $100 and $300 rather than $200; the costs of CRC
screening, complications and treatment – to account for
commercial rates at less than age 65, we multiplied
health-care costs of CRC screening, complications, and
treatment with a ratio of 1.35, as suggested by
Ladabaum et al. (33); the complexity of risk stratification
– by including a maximum of three instead of 60 risk
groups, where the 60 risk groups were merged into three
risk groups that were as equal in size as possible, or by as-
suming that every risk group would receive at least one
screening colonoscopy; and the adherence with polygenic
testing and subsequent screening – by assuming a more re-
alistic uptake of 60% for uniform screening (36), and of 54%,
57%, 60%, 63%, and 66% for risk-stratified screening. For an
equal uptake of 60%, we also varied the percentage of the
population that undergoes polygenic testing but does not
participate in CRC screening from 0% (base case) to 5% and
10%.
Results
Compared with no screening, uniform screening yielded 73 LYs
and 85 QALYs per 1000 40-year-olds, at a total cost of $1 626 000.
At a WTP threshold of $69 000 per QALY, risk-stratified screen-
ing with current discriminatory performance of polygenic test-
ing resulted in an equal number of QALYs (Table 1). Optimal
screening strategies ranged from one colonoscopy at age
60 years for the lowest-risk group (ie, those with an estimated
RR less than 0.6) to six colonoscopies at ages 40–80 years for the
highest-risk group (ie, those with an estimated RR greater than
3.1) (Figure 2A). However, more than 80% of individuals would
be offered two or three lifetime colonoscopies (Figure 2B). A
risk-stratified screening program including those strategies
would require 131 fewer colonoscopies per 1000 40-year-olds
than uniform screening yielding the same number of QALYs.
Although CRC screening and treatment costs would also be
$141 000 lower, the addition of polygenic testing costs implies
that total costs of risk-stratified screening were $59 000 higher
than those of uniform screening, suggesting that risk-stratified
screening would not be considered cost-effective. However, not
surprisingly, if polygenic testing cost $100 rather than $200 per
person, then risk-stratified screening would be considered
cost-effective. When assuming health-care costs based on
commercial rates rather than Medicare reimbursement, CRC
screening and treatment costs were higher both for uniform
and risk-stratified screening (Supplementary Appendix Table 1
available online). The cost difference would then equal
$168 000, suggesting that risk-stratified screening could be con-
sidered cost-effective if polygenic testing costs were less than
$168 per person.
With greater discriminatory performance of polygenic test-
ing, colonoscopies were more targeted to those in need
(Figure 2, A and B). With an increase in AUC value from 0.60 to
0.80, the fraction of the population offered six or more lifetime
colonoscopies increased from 0% to 12%, and the fraction in
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A







0.8 – 0.9 2 COLs, at ages 50 and 65 2 COLs, at ages 55 and 65
0.9 – 1.0
1.0 – 1.2 3 COLs, every 7 y, ages 55–70
1.2 – 1.3 3 COLs, every 10 y, ages 50–70
1.3 – 1.4
1.4 – 1.5









4.1 – 4.3 7 COLs, every 5y, ages 45–75
4.3 – 4.4
4.4 – 4.5




>5.9 12 COLs, every 3 y, 40–75
3 COLs, every 10 y, ages 50–75
2 COLs, at ages 55 and 70
No screening
1 COL, at age 60
9 COLs, every 5 y, ages 40–80
6 COLs, every 7 y, ages 40–80**
B
Recommended number of lifeme colonoscopies
Figure 2. A) Risk-stratified screening strategies by relative risk (RR) as estimated by a polygenic test with AUC value of 0.60–0.80, given a willingness-to-pay threshold
for risk-stratified screening that ensures that the entire risk-stratified screening program yields as least as many QALYs as a uniform screening program with colonos-
copies at ages 50, 60, and 70 years.* For every strategy, the number of lifetime colonoscopies, screening interval, and age range of screening is given (ie, “3 COLs, every
10 y, ages 50–75” refers to three lifetime colonoscopies with an interval of 10 years in individuals aged 50–75 years). B) Distribution of recommended numbers of lifetime
colonoscopies in the population for different AUC values. RR ¼ relative risk; AUC ¼ area under the receiver-operating characteristic curve; COLs ¼ colonoscopies.
*Willingness-to-pay threshold equals $69 000, $65 000, $56 700, $46 000, and $38 500 for AUC ¼ 0.60, 0.65, 0.70, 0.75, and 0.80, respectively. **For AUC ¼ 0.70, individuals
with an estimated RR of 3.6–4.1 are offered fewer lifetime screens than those with an estimated RR of 3.1–3.6, but the age range in which they are offered screening is
broader.
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which screening could be forgone increased from 0% to 48%.
This re-allocation of colonoscopies was associated with a re-
duced overall colonoscopy demand (Table 1) and made risk-
stratified screening cost saving compared to uniform screening
(Figure 3). Based on cost-effectiveness, risk-stratified screening
would therefore be preferred.
Sensitivity Analyses
Restricting the number of risk groups to three decreased the po-
tential benefit of risk-stratified screening and thus the cost sav-
ings (Figure 3). Risk-stratified screening would be cost saving
only if the AUC value of polygenic testing were to increase be-
yond 0.65. Offering at least one colonoscopy did not change the
results for AUC ¼ 0.60 because all risk groups were already of-
fered one or more colonoscopies in the base-case analysis. For
higher AUC values, a minimum of one colonoscopy did result in
lower cost savings.
The additional cost of polygenic testing could be com-
pensated for by a gain in screening participation. At current
discriminatory performance, a 5% increase would already
make risk-stratified screening less costly compared with
uniform screening (Figure 4A). However, if switching to
risk-stratified screening would imply a decrease in screen-
ing adherence of at least 5%, then risk-stratified screening
would not be cost saving, even if polygenic testing were
free.
With improved risk stratification, cost savings were less af-
fected by potential changes in screening participation (Figure 3,
B and C). Screening adherence could decrease with 5% (AUC ¼
0.70) or 10% (AUC ¼ 0.80), and risk-stratified screening would
still be more efficient than uniform screening.
If part of the population were to undergo polygenic testing
but not attend CRC screening, costs of risk-stratified screening
would increase, but its overall cost-effectiveness compared
with uniform screening was relatively insensitive to this param-
eter (Figure 3, D–F).
Discussion
This study shows that, under current discriminatory perfor-
mance of polygenic testing (ie, AUC ¼ 0.60), the health benefits
of risk-stratified screening are modest at most. At a current esti-
mated price of $200 per polygenic test, risk-stratified screening
is not cost-effective compared with uniform screening. This
could change if the discovery of more common genetic variants
were to increase the AUC value of polygenic testing beyond
0.65. Alternatively, risk-stratified screening could become cost-
effective at a lower price per polygenic test, or if adherence with
risk-stratified screening were higher than with current uniform
screening.
We estimated that from an AUC value of 0.65 onward, the re-
duction in CRC screening and treatment costs was sufficient to
cover the expected costs of polygenic testing, meaning that
replacing uniform with risk-stratified screening would be cost-
effective. However, colonoscopy uptake was assumed to remain
constant in these analyses, which is uncertain. In sensitivity
analyses we showed that if the increased complexity or poten-
tial problematic acceptability of a risk-stratified screening pro-
gram leads to a reduced colonoscopy uptake, then benefits of
risk stratification can easily be offset. Complexity and accept-
ability issues could partly be solved by including fewer risk cate-
gories and offering everyone at least one lifetime screen.
However, sensitivity analyses showed that especially including
fewer risk categories decreases the potential benefits of risk-
stratified screening.
This study represents an early exploration of the potential
benefit of risk-stratified screening based on common genetic
variants. In the base-case analysis, we assumed full adherence
both with genetic testing and subsequent recommended
Figure 3. Cost savings of replacing uniform screening with risk-stratified screening, when risk-stratified screening yields (at least) as many QALYs as uniform screen-
ing, for the base-case analysis and for sensitivity analyses on the assumed complexity of risk-stratified screening. AUC ¼ area under the receiver-operating characteris-
tic curve; QALY ¼ quality-adjusted life-year; RR ¼ relative risk. *For screening strategies by RR group, see Figure 2. **For screening strategies by RR group, see
Supplementary Appendix Figure 2 (available online). *** Individuals were grouped so that RR groups were as equal in size as possible. For screening strategies by RR
group, see Supplementary Appendix Figure 3 (available online).
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screening. In reality, people may refrain from polygenic testing
for various well-grounded reasons (40), and if tested, may not be
screened according to their optimal screening strategy. In a re-
cent US survey among people with an intermediate familial CRC
risk, three-fourths of participants said that they would probably
(47%) or definitely (27%) have SNP testing to estimate their CRC
risk (41). Actual uptake of polygenic testing in the general popu-
lation will depend on the implementation of the program and
the information provided to the public.
Although individuals with a family history of CRC are more
adherent with CRC screening guidelines (42), increased aware-
ness does not necessarily lead to increased adherence. One US
study showed that knowledge of elevated CRC risk increased
screening participation from 50% to 67% in whites, but, surpris-
ingly, it decreased screening participation from 54% to 33% in
individuals of other ethnicities (43). If implemented, screening
based on polygenic risk should be organized with care, with ade-
quate education and counseling before and after testing, so that
Figure 4. A–C) Estimated cost savings of replacing uniform screening with risk-stratified screening, when risk-stratified screening yields (at least) as many QALYs as
uniform screening, for different levels of adherence with risk-stratified screening. D–F) Estimated cost savings of replacing uniform screening with risk-stratified
screening, when risk-stratified screening yields (at least) as many QALYs as uniform screening, for different percentages of the population that does take polygenic
testing but does not participate in CRC screening. In these panels, an adherence of 60% was assumed both for uniform and risk-stratified screening.
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potential decreases both in overall adherence and adherence
within certain subgroups of the population could be minimized.
By varying the AUC value and other uncertain parameters,
we considered a broad spectrum of potential current and future
applications of risk-stratified screening. Nevertheless, this
study has some limitations. First, we did not assume any dis-
utility for having a polygenic test and for knowing your poly-
genic risk profile. Even though knowing that you have an
increased CRC risk can be burdensome, it also enables people to
get more intensive colonoscopy screening that could allow early
detection of cancer. Moreover, the majority will be reassured by
a relatively low CRC risk. Second, we presumed that our ability
to predict risk for CRC is equally robust across the entire spec-
trum of risk (ie, for those at decreased risk or increased risk),
which remains to be demonstrated empirically. Third, we did
not assume any additional costs for risk-stratified screening
Figure 4. Continued.
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compared with uniform screening, except for polygenic testing
costs. Additional costs will likely include those of implementing
the program (eg, planning and organizing both the introduction
of polygenic testing and the switch to risk-stratified screening,
educating health professionals and the general population),
counseling eligible individuals before and after polygenic test-
ing, and close monitoring of the program. Including those costs
would have negatively affected the cost-effectiveness of risk-
stratified screening, but because exact costs are currently un-
known, quantifying the effect is not possible.
We showed that risk-stratified colonoscopy screening may
become clinically relevant as more genetic variants associated
with CRC risk are identified. Although AUC values above 0.75
may not seem feasible, it has been estimated that from the total
number of SNPs associated with CRC risk, less than 10% have
currently been identified (16). Another way of increasing the
discriminatory ability of risk-stratification algorithms is by in-
cluding other risk factors, such as sex and family history of CRC
(18,44), and potentially also lifestyle (45). Efforts to develop mul-
tivariable risk models that include polygenic along with other
established risk factors might offer more rapid progress toward
risk-based screening for CRC rather than relying on polygenic
risk models.
Other studies evaluating the merit of screening based on
polygenic risk have considered a more simplified approach; for
example, with individuals being invited for regular screening
when their absolute disease risk was higher than a certain
threshold (17,46). For the UK population, it was estimated that
compared with uniform stool-based screening, risk-based
screening would reduce the number of men and women being
eligible for screening by 16% and 17%, respectively, at a cost of
10% and 8% fewer screen-detected CRC cases. Similar results
have been found for breast and prostate cancer screening
(46,47).
In conclusion, with the current discriminatory performance
of polygenic testing, CRC screening based on polygenic risk is
unlikely to be more cost-effective than uniform screening. This
is expected to change with a greater than 0.05 increase in dis-
criminatory test performance, a greater than 30% reduction in
polygenic testing costs, or a greater than 5% increase in adher-
ence with screening. Risk-stratification algorithms could further
be enhanced by including other risk factors, such as lifestyle. In
any case, risk-based screening would need to be implemented
and monitored very carefully to ensure a continued colonos-
copy uptake.
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